Ferrero, the Italian maker of Kinder and Tic Tacs, has made a bid for Belgian biscuit maker Delacre.
Delacre is controlled by Yildiz Holding, the Turkish owner of Godiva chocolate which recently established a London-based company called Pladis.
The report of the bid for Delacre, which makes premium biscuits, was made in La Stampa, the Italian daily newspaper.
The bid comes as Ferrero looks to diversify its business away from being too reliant on chocolate and reverse flagging sales in Italy and Germany.
Delacre would appear to be a good fit for Ferrero as it would enhance its status as a business which specialises in premium products.
No financial details of the deal were disclosed.
In June this year, it was announced that Yildiz Holdings is hiving off its confectionery and biscuit businesses into Pladis, saying the new business will allow it to be more “agile” and save costs.
Pladis is made up of UK biscuit brand McVitie’s; Turkish confectionery brands Ulker; Belgium premium chocolate brand Godiva; and US confectionery company DeMet’s Candy Company.
Pladis had overall revenues of around £5.2bn last year.
According to reports, Yildiz plans to list Pladis by 2020 on the London Stock Exchange by 2020.
Source: Food Ingredients First
A report from ingredients supplier Henley Bridge has warned that cocoa price increases of 15-20% for the first half of 2024 might continue into the second half of the year. Despite growth in global cocoa supply in 2021, unfavourable weather conditions and demand from emerging markets have led to supply deficits.
By carving out the ANH business, DSM-Firmenich would focus fully on its Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care divisions. Full focus on these businesses is expected to enhance commercial potential and synergies, supporting “consistent growth outlook alongside robust margins”.
Cargill and Enough are expanding their partnership to further develop nutritious and sustainable alternative meat and dairy solutions. Cargill has signed a commercial agreement to use and market Enough’s Abunda protein and has also invested in the company’s Series C growth funding round.